Pretreatment with a soluble activin type IIB receptor/Fc fusion protein improves hypoxia-induced muscle dysfunction

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 298, Issue 1, 2010, Pages

  Pistilli, Emidio E ^a   Bogdanovich, Sasha ^a   Mosqueira, Matias ^a   Lachey, Jennifer ^b   Seehra, Jasbir ^b   Khurana, Tejvir S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Acceleron Pharma   (United States)

Author keywords

Activin receptor; Muscle physiology; Muscle wasting; Myostatin

Indexed keywords

ACTIVIN RECEPTOR 2; ACTIVIN RECEPTOR 2B; HYBRID PROTEIN; UNCLASSIFIED DRUG;

ALTITUDE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ECCENTRIC MUSCLE CONTRACTION; EXTENSOR DIGITORUM LONGUS MUSCLE; HYPOXIA; MALE; MOUSE; MUSCLE ATROPHY; MUSCLE FUNCTION; MUSCLE MASS; NONHUMAN; PRIORITY JOURNAL; SIMULATION;

ACTIVIN RECEPTORS, TYPE II; ANIMALS; ANOXIA; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; MUSCLE CONTRACTION; MUSCLE, SKELETAL; ORGAN SIZE; TIME FACTORS;

EID: 73549119921     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00138.2009     Document Type: Article

References (28)

1. Akpan I, Goncalves MD, Dhir R, Yin X, Pistilli EE, Bogdanovich S, Khurana TS, Ucran J, Lachey J, Ahima RS. The effects of a soluble activin type IIB receptor on obesity and insulin sensitivity. Int J Obes. In press.
2. Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA, Ahima RS, Khurana TS. Functional improvement of dystrophic muscle by myostatin blockade. Nature 420: 418-421, 2002.
3. Bogdanovich S, Perkins KJ, Krag TO, Whittemore LA, Khurana TS. Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. FASEB J 19: 543-549, 2005.
4. Brooks SV, Faulkner JA. Contractile properties of skeletal muscles from young, adult and aged mice. J Physiol 404: 71-82, 1988.
5. Carpio Y, Acosta J, Morales R, Santisteban Y, Sanchez A, Estrada MP. Regulation of body mass growth through activin type IIB receptor in teleost fish. Gen Comp Endocrinol 160: 158-167, 2009.
6. Chen YF, Feng JA, Li P, Xing D, Zhang Y, Serra R, Ambalavanan N, Majid-Hassan E, Oparil S. Dominant-negative mutation of the TGF-β receptor blocks hypoxia-induced pulmonary vascular remodeling. J Appl Physiol 100: 564-571, 2006.
7. Cymerman A, Reeves JT, Sutton JR, Rock PB, Groves BM, Malconian MK, Young PM, Wagner PD, Houston CS. Operation Everest II: maximal oxygen uptake at extreme altitude. J Appl Physiol 66: 2446-2453, 1989.
8. de Caestecker M. The transforming growth factor-β superfamily of receptors. Cytokine Growth Factor Rev 15: 1-11, 2004.
9. Farkas GA, McCormick KM, Gosselin LE. Episodic hypoxia exacerbates respiratory muscle dysfunction in DMD (mdx) mice. Muscle Nerve 36: 708-710, 2007.
10. Green HJ, Sutton JR, Cymerman A, Young PM, Houston CS. Operation Everest II: adaptations in human skeletal muscle. J Appl Physiol 66: 2454-2461, 1989.
11. Grundtman C, Lundberg IE. Pathogenesis of idiopathic inflammatory myopathies. Curr Rheumatol Rep 8: 188-195, 2006.
12. 2 uptake and performance by acute hypoxia in dog muscle in situ. J Appl Physiol 65: 815-821, 1988.
13. Hoppeler H, Vogt M. Muscle tissue adaptations to hypoxia. J Exp Biol 204: 3133-3139, 2001.
14. Lachey JL, Pullen AE, Pearsall R, Seehra JS. Novel myostatin inhibitors increase muscle mass in wild-type and mdx mice. Neuromuscular Disorders 17: 785, 2007.
15. Lee SJ. Quadrupling muscle mass in mice by targeting TGF-β signaling pathways. PLoS ONE 2: e789, 2007.
16. Lee SJ. Sprinting without myostatin: a genetic determinant of athletic prowess. Trends Genet 23: 475-477, 2007.
17. Lee SJ, Reed LA, Davies MV, Girgenrath S, Goad ME, Tomkinson KN, Wright JF, Barker C, Ehrmantraut G, Holmstrom J, Trowell B, Gertz B, Jiang MS, Sebald SM, Matzuk M, Li E, Liang LF, Quattlebaum E, Stotish RL, Wolfman NM. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci USA 102: 18117-18122, 2005.
18. Lynch GS, Hinkle RT, Chamberlain JS, Brooks SV, Faulkner JA. Force and power output of fast and slow skeletal muscles from mdx mice 6-28 months old. J Physiol 535: 591-600, 2001.
19. MacDougall JD, Green HJ, Sutton JR, Coates G, Cymerman A, Young P, Houston CS. Operation Everest II: structural adaptations in skeletal muscle in response to extreme simulated altitude. Acta Physiol Scand 142: 421-427, 1991.
20. Martinelli M, Winterhalder R, Cerretelli P, Howald H, Hoppeler H. Muscle lipofuscin content and satellite cell volume is increased after high altitude exposure in humans. Experientia 46: 672-676, 1990.
21. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member. Nature 387: 83-90, 1997.
22. McPherron AC, Lee SJ. Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci USA 94: 12457-12461, 1997.
23. Morrison BM, Lachey JL, Warsing LC, Ting BL, Pullen AE, Underwood KW, Kumar R, Sako D, Grinberg A, Wong V, Colantuoni E, Seehra JS, Wagner KR. A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis. Exp Neurol 217: 258-268, 2009.
24. Mosher DS, Quignon P, Bustamante CD, Sutter NB, Mellersh CS, Parker HG, Ostrander EA. A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genet 3: e79, 2007.
25. Schuelke M, Wagner KR, Stolz LE, Hubner C, Riebel T, Komen W, Braun T, Tobin JF, Lee SJ. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 350: 2682-2688, 2004.
26. Wagner KR, McPherron AC, Winik N, Lee SJ. Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol 52: 832-836, 2002.
27. Whittemore LA, Song K, Li X, Aghajanian J, Davies M, Girgenrath S, Hill JJ, Jalenak M, Kelley P, Knight A, Maylor R, O'Hara D, Pearson A, Quazi A, Ryerson S, Tan XY, Tomkinson KN, Veldman GM, Widom A, Wright JF, Wudyka S, Zhao L, Wolfman NM. Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem Biophys Res Commun 300: 965-971, 2003.
28. Willman G, Bogdanovich S, Baby SM, Wiesen MHJ, Lahiri S, Khurana TS. Role of hypoxia-mediated muscle damage in meuromuscular disorders (Abstract). Neuromuscular Disorders 16: S189, 2006.